Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults
Drug and Therapeutics Bulletin · 2026
DOI: 10.1136/dtb.2022.000065 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug and Therapeutics Bulletin, 2026. Verfasst von Lucy Prentice und 1 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics, Gynaecology and Reproductive Sciences, The University of Auckland - Grafton Campus, Auckland, New Zealand lucy.prentice@auckland.ac.nz. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Polyendocrine metabolic ovarian syndrome (PMOS), previously named polycystic ovary syndrome, is a common endocrine disorder in women of reproductive age. It is associated with excessive levels of androgens and ovulatory dysfunction and has reproductive, metabolic and psychological impacts across the lifespan. Pharmacotherapy in PMOS should be directed at the concerns of the individual patient and may include the combined contraceptive pill, antiandrogen agents, metformin, antiobesity agents and ovulation induction agents. A narrative review of non-hormonal therapies was conducted. Metformin is associated with modest reductions in body weight and improves metabolic and anthropometric outcomes. Glucagon-like peptide-1 receptor agonists are an attractive option for weight loss although specific data in PMOS populations remain limited and there are safety considerations in the periconceptual setting. For ovulation induction, letrozole is the first-line agent of choice based on reassuring safety and efficacy data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obstetrics, Gynaecology and Reproductive Sciences, The University of Auckland - Grafton Campus, Auckland, New Zealand lucy.prentice@auckland.ac.nz.
- Monash Centre for Health Research and Implementation, Clayton, Victoria, Australia.
Zitieren
APA
Prentice, L., & Rassie, K. (2026). Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.2022.000065
Vancouver
Prentice L, Rassie K. Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults. Drug and Therapeutics Bulletin. 2026. doi:10.1136/dtb.2022.000065
BibTeX
@article{Prentice2026,
author = {Prentice, Lucy and Rassie, Kate},
title = {Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults},
journal = {Drug and Therapeutics Bulletin},
year = {2026},
doi = {10.1136/dtb.2022.000065}
}
EUVIMED